AI Article Synopsis
- Previous research highlighted PRMT5 as a target for treating cancers lacking the MTAP gene (MTAP del), but effective small-molecule inhibitors like MRTX1719 were not fully explored until now.
- MRTX1719 specifically inhibits PRMT5 activity in the presence of elevated MTA found in MTAP del cancers, showing significant anti-tumor effects and selective efficacy in cancer cells with MTAP deletions.
- Early clinical trials indicate that MRTX1719 may help patients with various cancers carrying the MTAP deletion, representing a promising treatment option for about 10% of cancer patients with this specific genetic marker.
Article Abstract
Unlabelled: Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti-vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non-small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study.
Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618744 | PMC |
| http://dx.doi.org/10.1158/2159-8290.CD-23-0669 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of PRMT5 as a therapeutic target in cholangiocarcinoma.
Gut
December 2024
Hepatology, CIMA-University of Navarra, Pamplona, Spain
Background: Cholangiocarcinoma (CCA) is a very difficult-to-treat cancer. Chemotherapies are little effective and response to immune checkpoint inhibitors is limited. Therefore, new therapeutic strategies need to be identified.
View Article and Find Full Text PDFMagmatic immiscibility and the origin of magnetite-(apatite) iron deposits.
Nat Commun
December 2023
Department of Earth & Atmospheric Sciences, University of Alberta, Edmonton, AB, T6G 2E3, Canada.
The origin of magnetite-(apatite) iron deposits (MtAp) is one of the most contentious issues in ore geology with competing models that range from hydrothermal to magmatic processes. Here we report melt inclusions trapped in plagioclase phenocrysts in andesite hosting the MtAp mineralization at El Laco, Chile. The results of our study reveal that individual melt inclusions preserve evidence of complex processes involved in melt immiscibility, including separation of Si- and Fe-rich melts, the latter hosting Cu sulfide-rich, phosphate-rich, and residual C-O-HFSE-rich melts, with their melting temperature at 1145 °C.
View Article and Find Full Text PDFSERS analysis of cancer cell-secreted purines reveals a unique paracrine crosstalk in MTAP-deficient tumors.
Proc Natl Acad Sci U S A
December 2023
Center for Cooperative Research in Biomaterials (CIC biomaGUNE), Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián 20014, Spain.
The tumor microenvironment (TME) is a dynamic pseudoorgan that shapes the development and progression of cancers. It is a complex ecosystem shaped by interactions between tumor and stromal cells. Although the traditional focus has been on the paracrine communication mediated by protein messengers, recent attention has turned to the metabolic secretome in tumors.
View Article and Find Full Text PDFMRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Cancer Discov
November 2023
Mirati Therapeutics, Inc., San Diego, California.
Article Synopsis
- Previous research highlighted PRMT5 as a target for treating cancers lacking the MTAP gene (MTAP del), but effective small-molecule inhibitors like MRTX1719 were not fully explored until now.
- MRTX1719 specifically inhibits PRMT5 activity in the presence of elevated MTA found in MTAP del cancers, showing significant anti-tumor effects and selective efficacy in cancer cells with MTAP deletions.
- Early clinical trials indicate that MRTX1719 may help patients with various cancers carrying the MTAP deletion, representing a promising treatment option for about 10% of cancer patients with this specific genetic marker.
Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights.
Eur Urol
July 2023
Occupational and Environmental Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Article Synopsis
- The study aims to identify new genetic variants that increase the risk of bladder cancer using data from 32 studies involving 13,790 patients and 343,502 control subjects of European descent.
- Researchers discovered multiple novel susceptibility loci and enhanced signals in known regions, achieving a total of 24 significant markers linked to bladder cancer risk.
- The findings indicate that the risk is further influenced by factors such as sex and smoking status, with a polygenic risk score showing a significant difference in lifetime risk for bladder cancer based on genetic predisposition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!